NTLA insider buying and SEC filings, explained
Intellia Therapeutics, Inc. · CIK 1652130
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$1.4M
Insiders who bought
1
Sold (not marked 10b5-1)
$956K
Planned sales (10b5-1)
$1.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Nov 2, 2026 | Planned (10b5-1) | John M. Leonard (CEO and Director) sold 9,000 shares at about $11.99 ($108K), marked as a 10b5-1 plan trade. Holdings down 1% to 1,138,064 shares. | SEC filing Filed Nov 3, 2026, 4:20 PM ET |
| Oct 2, 2026 | Sale | Michael P Dube (VP, Chief Accounting Officer) sold 1,864 shares at $12.43 ($23K). Holdings down 3% to 65,022 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 6, 2026, 4:05 PM ET |
| Aug 20–21, 2026 | Planned (10b5-1) | John M. Leonard (CEO and Director) sold 22,675 shares between Aug 20 and Aug 21 at about $12.65 ($287K), marked as a 10b5-1 plan trade. Holdings down 2% to 1,147,064 shares. | SEC filing Filed Aug 24, 2026 |
| Jul 22, 2026 | Sale | Edward J Dulac III (CFO) sold 8,111 shares at about $11.25 ($91K). Holdings down 5% to 148,175 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 24, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Edward J Dulac III (CFO) sold 4,677 shares at $18.00 ($84K), marked as a 10b5-1 plan trade. Holdings down 3% to 156,286 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Sale | Michael P Dube (VP, Chief Accounting Officer) sold 2,641 shares at about $16.78 ($44K). Holdings down 4% to 66,886 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 6, 2026 |
| Mar 2, 2026 | Sale | James Basta (EVP, General Counsel) sold 1,211 shares at $13.78 ($17K). Holdings down 1% to 156,794 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Eliana Clark (EVP, Chief Technical Officer) sold 607 shares at $13.78 ($8K). Holdings down 1% to 93,864 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Jan 5, 2026 | Sale | John M. Leonard (CEO and Director) sold 34,146 shares at $9.21 ($314K). Holdings down 3% to 1,013,339 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Sale | Birgit C Schultes (EVP, Chief Scientific Officer) sold 8,508 shares at $9.21 ($78K). Holdings down 8% to 98,533 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Sale | James Basta (EVP, General Counsel) sold 10,397 shares at $9.21 ($96K). Holdings down 9% to 101,528 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Open-market purchase | Fred E Cohen (Director) bought 150,000 shares at about $9.35 ($1.4M) in an open-market purchase. Holdings up 261% to 207,453 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Sale | David Lebwohl (EVP, Chief Medical Officer) sold 11,903 shares at $9.21 ($110K). Holdings down 9% to 121,249 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Sale | Eliana Clark (EVP, Chief Technical Officer) sold 9,515 shares at $9.21 ($88K). Holdings down 10% to 87,118 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Sale | Edward J Dulac III (CFO) sold 6,379 shares at $9.21 ($59K). Holdings down 6% to 99,683 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5, 2026 | Sale | Michael P Dube (VP, Chief Accounting Officer) sold 2,989 shares at $9.21 ($28K). Holdings down 5% to 52,277 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Dec 11, 2025 | Planned (10b5-1) | John M. Leonard (CEO and Director) sold 88,146 shares at about $9.49 ($836K), marked as a 10b5-1 plan trade. Holdings down 8% to 1,038,928 shares. | SEC filing Filed Dec 12, 2025 |
16 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NTLA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.